Inovio Pharmaceuticals (NASDAQ: INO) was among the first to start clinical trials on a coronavirus vaccine candidate. The U.S. Food and Drug Administration (FDA) last fall placed one of Inovio's vaccine trials on a partial clinical hold, and the program fell behind. Now, Inovio's candidate is in phase 2.
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO).